Patients & Families

Denali is pursuing new treatments engineered to cross the blood-brain barrier to improve the lives of people impacted by neurodegenerative diseases. 

We are unified on a singular purpose to discover and develop therapeutics to defeat degeneration.

Our community

Current Clinical Trials

Before a new treatment can be made available to the general public, multiple studies – referred to as clinical trials – must be conducted to evaluate the safety and effectiveness of the investigational treatment.

Denali and our research partners are conducting clinical trials in the following disease areas. Learn more about these ongoing studies by visiting ClinicalTrials.gov.

PARKINSON’S DISEASE

Our investigational LRRK2 inhibitor treatment BIIB122/DNL151 aims to slow disease progression and treat the underlying cause of Parkinson's disease. Learn more about our investigational treatment and plans for future late-stage trials by visiting EngageParkinson's.

HUNTER SYNDROME

We are advancing therapies that aim to address the cognitive, behavioral, and physical aspects of MPS II and other MPS disorders. Learn more about our investigational brain-penetrant enzyme replacement treatment DNL310 for Hunter syndrome by visiting EngageHunter.

AMYOTROPHIC LATERAL SCLEROSIS (ALS)

We are focused on developing potential treatments for ALS that aim to slow disease progression, including advancing  clinical trials of our investigational eIF2B activator treatment DNL343.  Visit   ClinicalTrials.gov  to learn more about this study.   

The Engage sites are intended for United States audiences only. These investigational treatments are not approved by any Health Authority.

Ongoing research in neurodegenerative diseases

We have a broad pipeline of early-stage programs also targeting neurodegenerative diseases including Alzheimer's, Frontotemporal Dementia (FTD) and Lysosomal storage disorders. Visit our pipeline to learn more.

Our Commitment

Our commitment to you

We listen to people living with neurodegenerative diseases. We engage individuals, families, caregivers and advocacy groups in our work as we strive to develop impactful solutions that address your needs.

Contact our patient advocacy team to learn more at patients@dnli.com

OUR EXPANDED ACCESS POLICY (EAP) TO INVESTIGATIONAL DRUGS

Denali understands that there are some cases when a patient is unable to participate in a clinical trial, and other treatment options have been exhausted. In those cases, the patient's physician may choose to request access to an investigational drug outside of a clinical trial via what is termed Expanded Access in the United States.

Currently, participation in clinical trials is the only way for patients to gain access to Denali's investigational therapies. As more clinical data on the safety and efficacy of these investigational therapies become available, we may review and update our policy on Expanded Access.